TheNewswire – April 6 th 2021 Solarvest BioEnergy Inc. is pleased to announce that it and The Scoular Company are exploring a potential business relationship related to developing a sustainable supply of Omega-3 fatty acids, a globally important and limited resource, through a non-binding development program. The goal of the program is to develop protocols and process data for the efficient production of …
TheNewswire – April 6 th 2021 Solarvest BioEnergy Inc. (“Solarvest”, or the “Company”) (TSXV:SVS), is pleased to announce that it and The Scoular Company (“Scoular”) are exploring a potential business relationship related to developing a sustainable supply of Omega-3 fatty acids, a globally important and limited resource, through a non-binding development program. The goal of the program is to develop protocols and process data for the efficient production of commercial volumes of Omega-3 fatty acids.
This program satisfies both companies’ commitment to the sustainable supply of health enhancing food and will utilize SVS’s algae platform expertise combined with Scoular’s extensive knowledge, experience and activity in the global agricultural supply chain. Scoular supports responsible marine product sourcing, and providing the marketplace with alternative food and feedstuffs that have a positive economic, environmental and social impact .
The Scoular Company is a 128-year-old company with $4.6 billion in sales. Scoular creates safe and reliable supply chain solutions for end-users and suppliers of grain, feed ingredients and food ingredients. From more than 100 offices and facilities in North America and Asia, Scoular’s 1,000-plus employees lead the way by buying, selling, storing, handling and processing grain and ingredients as well as managing transportation and logistics for customers around the world.
Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully demonstrated the expression of BMP, a high value therapeutic protein, viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.
For further information contact:
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the Company’s expectations and projections.
Copyright (c) 2021 TheNewswire – All rights reserved.
News Provided by TheNewsWire via QuoteMedia